Bristol-Myers Squibb Company
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Bristol-Myers Squibb Company |
Stock Symbol : | NYSE: BMY |
Class Period Start: | 01/27/2015 |
Class Period End: | 10/09/2016 |
Lead Plaintiff motion: | 04/10/2018 |
Date Filed: | 02/09/2018 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Northern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the April 10, 2018 lead plaintiff deadline in a class action lawsuit filed against Bristol-Myers Squibb Co (NYSE: BMY) (“Bristol-Myers” or “the Company”). The suit is pending in the U.S. District Court for the Northern District of California and investors, who purchased Bristol-Myers Squibb Company securities between January 27, 2015 and October 9, 2016, have until April 10, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Bristol-Myers Squibb Company securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Bristol-Myers' CheckMate-026 trial was more likely to fail than Defendants were representing; that Bristol- Myers' CheckMate-026 trial failed more severely than the Company indicated in its August 5, 2016 announcements and disclosures; and that, as a result of the foregoing, Defendants' statements about Bristol-Myers' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. On August 5, 2016, the Company announced that its CheckMate-026 trial did not meet its primary endpoint of progression-free survival. On this news, NYSE: BMY fell 16% to close at $63.28 per share on August 5, 2016. On October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months. On this news, NYSE: BMY fell above 10%, to close at $49.81 per share on October 10, 2016. If you were negatively impacted by your investment in Bristol-Myers Squibb Company securities between January 27, 2015 and October 9, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |